Company Overview and News
Pantoro Ltd (ASX:PNR) has achieved full year gold production of 52,203 ounces at the Nicolsons mine, within its targeted range of 50,000 – 55,000 ounces.
Pantoro Ltd (ASX:PNR) managing director Paul Cmrlec speaks to Proactive Investors about the gold producer's operations at the multi-faceted Halls Creek Project, in the Kimberley Region of Western Australia.
Pantoro Ltd (ASX:PNR) has received new high-grade drill results from the Rowdies deposit within the Halls Creek Gold Project in Western Australia.
Pantoro Ltd’s (ASX:PNR) recently installed ore sorter and crushing circuit at the Nicolsons Project in Western Australia has been commissioned and is operating to expectation.
Pantoro Ltd (ASX:PNR) has updated the indicated and inferred resource at its Wagtail underground mine in Western Australia’s Kimberley region to 574,000 tonnes at 6.8 g/t gold for 126,000 ounces.
Pantoro Ltd (ASX:PNR) produced a solid 13,385 ounces of gold in the March quarter from its 100% owned Nicolsons Gold Mine within the Halls Creek Project in Western Australia.
Pantoro Ltd (ASX:PNR) has extended the depth and strike of gold mineralisation at the Wagtail underground mine in Western Australia’s Kimberley region.
Pantoro Ltd (ASX:PNR) is a zero-debt company after making its final repayment under the gold pre-payment facility with the Commonwealth Bank of Australia (ASX:CBA).
Pantoro Ltd (ASX:PNR) has identified deep high-grade gold extensions at the Nicolsons underground mine which forms part of the Halls Creek project in Western Australia.
3h - Asif
Overview Adaptimmune Therapeutics is a clinical-stage biopharmaceutical company focused on providing novel cell therapies to patients, particularly in solid tumors. The company's comprehensive and proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (“TCRs”), and produce therapeutic candidates for administration to patients. Using its affinity engineered TCRs, the company aim to become a fully integrated cell therapy company and to be the first company to have a TCR T-cell approved for a solid tumor indication. Adaptimmune Therapeutics has four SPEAR T-cells in clinical trials, MAGE-A10, MAGE-A4, AFP and NY-ESO. Phase 1/2 clinical trials are ongoing in patients with various cancer tumor types including urothelial, melanoma, head and neck, ovarian, esophageal, gastric, multiple myeloma, hepatocellular cancers and in synovial sarcoma, myxoid round cell liposarcoma...
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
Silicon Investor Message Boards
This table lists all message boards related to ASX:PNR / PANTORO LIMITED on message board site Silicon Investor.
|Pentair, Inc. (PNR)||PNRG: PrimeEnergy Corporation|
|PNRL - What about Penril?|